REFERENCES
1. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2025. Diabetes Care. 2025;48:S181-206.
2. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925-66.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102:S1-127.
4. Wilmot EG, Moore P, Sathyapalan T, et al. ; FreeDM2 Study Group. Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial. Lancet Diabetes Endocrinol. 2026;14:463-74.
5. Aleppo G, Beck RW, Bailey R, et al. ; MOBILE Study Group, Type 2 Diabetes Basal Insulin Users: The Mobile Study (MOBILE) Study Group. The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin. Diabetes Care. 2021;44:2729-37.
6. Martens T, Beck RW, Bailey R, et al. ; MOBILE Study Group. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021;325:2262-72.
7. Dang A, Arora D, Rane P. Role of digital therapeutics and the changing future of healthcare. J Family Med Prim Care. 2020;9:2207-13.
8. Phan P, Mitragotri S, Zhao Z. Digital therapeutics in the clinic. Bioeng Transl Med. 2023;8:e10536.
9. Ribba B, Peck R, Hutchinson L, Bousnina I, Motti D. Digital therapeutics as a new therapeutic modality: a review from the perspective of clinical pharmacology. Clin Pharmacol Ther. 2023;114:578-90.
10. Bandura A. Self efficacy: the exercise of control. New York: W.H. Freeman and Company; 1997. Available from https://search.worldcat.org/zh-cn/title/36074515. [accessed 24 September 2026].
11. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.
12. U. S. Food and Drug Administration. Policy for device software functions and mobile medical applications: guidance for industry and Food and Drug Administration staff. Silver Spring, MD: U.S. Food and Drug Administration; 2022. Available from https://www.fda.gov/media/80958/download. [accessed 24 September 2026].
13. U. S. Food and Drug Administration. Clinical decision support software: guidance for industry and Food and Drug Administration staff. Silver Spring, MD: U.S. Food and Drug Administration; 2022. Available from https://www.fda.gov/media/109618/download. [accessed 24 September 2026].
14. McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014;67:267-77.
15. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8:431-40.
16. FDA NIH Biomarker Working Group. BEST Biomarkers EndpointS and other Tools Resource. Silver Spring, MD: Food and Drug Administration; Bethesda, MD: National Institutes of Health; 2016. Available from https://www.ncbi.nlm.nih.gov/books/NBK326791/. [accessed 24 September 2026].
17. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42:1593-603.
18. Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther. 2019;21:81-5.
19. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42:400-5.
20. Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care. 2020;8:e000991.
